NCT02427308View on ClinicalTrials.gov

Treatment of Leishmaniasis With Impavido® (Miltefosine): Pregnancy Registry

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

July 31, 2015

Primary Completion Date

March 28, 2025

Study Completion Date

March 28, 2025

Conditions
Leishmaniasis or Other Uses of Miltefosine
Interventions
DRUG

Miltefosine

target dose = 2.5 mg/kg/day for 28 days

Trial Locations (1)

Unknown

Fast Track, North Potomac

Sponsors
All Listed Sponsors
lead

Knight Therapeutics (USA) Inc

INDUSTRY